Straits Times Index
3,308.48 +0.58 (+0.02%) Nikkei
38,887.10 +270.00 (+0.70%) Hang Seng
18,837.79 -357.81 (-1.86%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,509.05 -745.62 (-1.06%) CMC Crypto 200
1,512.33 -14.09 (-0.92%)
NuCana plc (NCNA)
After hours:
| Previous close | 3.5500 |
| Open | 3.7000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.4615 - 3.7019 |
| 52-week range | 3.4000 - 23.7500 |
| Volume | |
| Avg. volume | 83,377 |
| Market cap | 7.819M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -16.6700 |
| Earnings date | 14 Aug 2024 - 19 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 125.24 |
- GlobeNewswire
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Event: TD Cowen’s 5th Annual Oncology Innovation SummitDate: Tuesday, May 28, 2024Time: 8:30 AM EDTLocation: Virtual The presentation will be webcast live and available for replay under “Events & Presentations” in the Inve
- GlobeNewswire
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2024 and provided an update on its broad
- GlobeNewswire
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the matter is c
